WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006124529) GLP-1 PEGYLATED COMPOUNDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/124529    International Application No.:    PCT/US2006/018284
Publication Date: 23.11.2006 International Filing Date: 11.05.2006
IPC:
A61K 47/48 (2006.01), C07K 14/605 (2006.01), A61P 3/10 (2006.01)
Applicants: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US) (For All Designated States Except US).
GLAESNER, Wolfgang [DE/US]; (US) (For US Only).
MAYER, John, Philip [US/US]; (US) (For US Only).
MILLICAN, Rohn, Lee, Junior [US/US]; (US) (For US Only).
VICK, Andrew, Mark [US/US]; (US) (For US Only).
ZHANG, Lianshan [US/US]; (US) (For US Only)
Inventors: GLAESNER, Wolfgang; (US).
MAYER, John, Philip; (US).
MILLICAN, Rohn, Lee, Junior; (US).
VICK, Andrew, Mark; (US).
ZHANG, Lianshan; (US)
Agent: COX, Gregory, A.; ELI LILLY AND COMPANY, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US)
Priority Data:
60/680,688 13.05.2005 US
Title (EN) GLP-1 PEGYLATED COMPOUNDS
(FR) COMPOSES GLP-1 PEGYLES
Abstract: front page image
(EN)The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (ß) cell population, or decreasing gastric or intestinal motility.
(FR)L'invention concerne des composés GLP-1 couplés à deux molécules de polyéthylèneglycol ou des dérivés de celles-ci, ces composés permettant d'obtenir un peptide biologiquement actif présentant une demi-vie prolongée et une clairance plus lente comparativement à celles d'un peptide non pégylé. Ces composés GLP-1 pégylés et ces compositions sont utiles pour traiter des états ou des troubles pour lesquels une réduction de la glycémie, de la ration alimentaire et de la vidange gastrique ou intestinale et une augmentation de la population de cellules bêta (ß) ou une réduction de la motilité gastrique ou intestinale sont bénéfiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)